Cystic fibrosis transmembrane conductance regulator modulators in cystic fibrosis: current perspectives

References

• RiordanJRommensJKeremBIdentification of the cystic fibrosis gene: cloning and characterization of complementary DNAScience19892454922106610732475911
   PubMed Web of Science ®Google Scholar
• HuauxFNoelSDhoogheBDysregulated proinflammatory and fibrogenic phenotype of fibroblasts in cystic fibrosisPLoS One201385e6434123734196
   PubMed Web of Science ®Google Scholar
• MarcorellesPFriocourtGUguenALedéFFérecCLaquerrièreACystic fibrosis transmembrane conductance regulator protein (CFTR) expression in the developing human brain: comparative immunohistochemical study between patients with normal and mutated CFTRJ Histochem Cytochem2014621179180125062999
   PubMed Web of Science ®Google Scholar
• GaoZSunHYLauCPChin-Wan FungPLiGREvidence for cystic fibrosis transmembrane conductance regulator chloride current in swine ventricular myocytesJ Mol Cell Cardiol20074219810517112538
   PubMed Web of Science ®Google Scholar
• BonfieldTLHodgesCACottonCUDrummMLAbsence of the cystic fibrosis transmembrane regulator (Cftr) from myeloid-derived cells slows resolution of inflammation and infectionJ Leukoc Biol20129251111112222859830
   PubMed Web of Science ®Google Scholar
• DiABrownMEDeriyLVCFTR regulates phagosome acidification in macrophages and alters bactericidal activityNat Cell Biol20068993394416921366
   PubMed Web of Science ®Google Scholar
• PainterRGValentineVGLansonNACFTR expression in human neutrophils and the phagolysosomal chlorination defect in cystic fibrosisBiochemistry20064534102601026916922501
   PubMed Web of Science ®Google Scholar
• ZengerlingSTsuiLCGrzeschikKHOlekKRiordanJRBuchwaldMMapping of DNA markers linked to the cystic fibrosis locus on the long arm of chromosome 7Am J Hum Genet19874032282363472464
   PubMed Web of Science ®Google Scholar
• TsuiLBuchwaldMBarkerDCystic fibrosis locus defined by a genetically linked polymorphic DNA markerScience19852304729105410572997931
   PubMed Web of Science ®Google Scholar
• GadsbyDCVerganiPCsanadyLThe ABC protein turned chloride channel whose failure causes cystic fibrosisNature2006440708347748316554808
   PubMed Web of Science ®Google Scholar
• SebastianARishishwarLWangJOrigin and evolution of the cystic fibrosis transmembrane regulator protein R domainGene2013523213714623578801
   PubMed Web of Science ®Google Scholar
• ChengSHRichDPMarshallJGregoryRJWelshMJSmithAEPhosphorylation of the R domain by cAMP-dependent protein kinase regulates the CFTR chloride channelCell1991665102710361716180
   PubMed Web of Science ®Google Scholar
• CsanádyLSeto-YoungDChanKWPreferential phosphorylation of R-domain Serine 768 dampens activation of CFTR channels by PKAJ Gen Physiol2005125217118615657296
   PubMed Web of Science ®Google Scholar
• BilletAJiaYJensenTRiordanJRHanrahanJWRegulation of the cystic fibrosis transmembrane conductance regulator anion channel by tyrosine phosphorylationFASEB J20152993945395326062600
   PubMed Web of Science ®Google Scholar
• HallowsKRKobingerGPWilsonJMWittersLAFoskettJKPhysiological modulation of CFTR activity by AMP-activated protein kinase in polarized T84 cellsAm J Physiol Cell Physiol20032845C1297C130812519745
   PubMed Web of Science ®Google Scholar
• SeavillekleinGAmerNEvagelidisAPKC phosphorylation modulates PKA-dependent binding of the R domain to other domains of CFTRAm J Physiol Cell Physiol20082955C1366C137518799655
   PubMed Web of Science ®Google Scholar
• CsanádyLChanKWSeto-YoungDKopscoDCNairnACGadsbyDCSevered channels probe regulation of gating of cystic fibrosis transmembrane conductance regulator by its cytoplasmic domainsJ Gen Physiol2000116347750010962022
   PubMed Web of Science ®Google Scholar
• ChappeVIrvineTLiaoJEvagelidisAHanrahanJWPhosphorylation of CFTR by PKA promotes binding of the regulatory domainEMBO J200524152730274016001079
   PubMed Web of Science ®Google Scholar
• HegedűsTAleksandrovAMengosACuiLJensenTJRiordanJRRole of individual R domain phosphorylation sites in CFTR regulation by protein kinase ABiochim Biophys Acta2009178861341134919328185
   PubMed Web of Science ®Google Scholar
• WilkinsonDJStrongTVMansouraMKCFTR activation: additive effects of stimulatory and inhibitory phosphorylation sites in the R domainAm J Physiol Lung Cell Mol Physiol19972731L127L133
   Web of Science ®Google Scholar
• VaisHZhangRReenstraWWDibasic phosphorylation sites in the R domain of CFTR have stimulatory and inhibitory effects on channel activationAm J Physiol Cell Physiol20042873C737C74515140750
   PubMed Web of Science ®Google Scholar
• BozokyZKrzeminskiMMuhandiramRRegulatory R region of the CFTR chloride channel is a dynamic integrator of phospho-dependent intra- and intermolecular interactionsProc Natl Acad Sci U S A201311047E4427E443624191035
   PubMed Web of Science ®Google Scholar
• BozokyZKrzeminskiMChongPAForman-KayJDStructural changes of CFTR R region upon phosphorylation: a plastic platform for intramolecular and intermolecular interactionsFEBS J2013280184407441623826884
   PubMed Web of Science ®Google Scholar
• FarinhaCMSwiatecka-UrbanABrautiganDLJordanPRegulatory crosstalk by protein kinases on CFTR trafficking and activityFront Chem20164126835446
   PubMed Web of Science ®Google Scholar
• MoranOOn the structural organization of the intracellular domains of CFTRInt J Biochem Cell Biol20145271424513531
   PubMed Web of Science ®Google Scholar
• HwangTCSheppardDNGating of the CFTR Cl(−) channel by ATP-driven nucleotide-binding domain dimerisationJ Physiol2009587pt 102151216119332488
   PubMed Web of Science ®Google Scholar
• LewisHABuchananSGBurleySKStructure of nucleotide-binding domain 1 of the cystic fibrosis transmembrane conductance regulatorEMBO J200423228229314685259
   PubMed Web of Science ®Google Scholar
• VerganiPLocklessSWNairnACGadsbyDCCFTR channel opening by ATP-driven tight dimerization of its nucleotide-binding domainsNature2005433702887688015729345
   PubMed Web of Science ®Google Scholar
• ZhouZWangXLiuHYZouXLiMHwangTCThe two ATP binding sites of cystic fibrosis transmembrane conductance regulator (CFTR) play distinct roles in gating kinetics and energeticsJ Gen Physiol2006128441342216966475
   PubMed Web of Science ®Google Scholar
• AndersonMGregoryRThompsonSDemonstration that CFTR is a chloride channel by alteration of its anion selectivityScience199125350162022051712984
   PubMed Web of Science ®Google Scholar
• LinsdellPMechanism of chloride permeation in the cystic fibrosis transmembrane conductance regulator chloride channelExp Physiol200691112312916157656
   PubMed Web of Science ®Google Scholar
• LinsdellPHanrahanJWAdenosine triphosphate–dependent asymmetry of anion permeation in the cystic fibrosis transmembrane conductance regulator chloride channelJ Gen Physiol199811146016149524141
   PubMed Web of Science ®Google Scholar
• GouldNSMinEMartinRJDayBJCFTR is the primary known apical glutathione transporter involved in cigarette smoke induced adaptive responses in the lungFree Radic Biol Med20125271201120622266045
   PubMed Web of Science ®Google Scholar
• LinsdellPHanrahanJWGlutathione permeability of CFTRAm J Physiol Cell Physiol19982751C323C326
   Web of Science ®Google Scholar
• TangLFatehiMLinsdellPMechanism of direct bicarbonate transport by the CFTR anion channelJ Cyst Fibros20098211512119019741
   PubMed Web of Science ®Google Scholar
• QuintonPMChloride impermeability in cystic fibrosisNature198330158994214226823316
   PubMed Web of Science ®Google Scholar
• QuintonPMCystic fibrosis: impaired bicarbonate secretion and mucoviscidosisLancet2008372963641541718675692
   PubMed Web of Science ®Google Scholar
• KnowlesMGatzyJBoucherRIncreased bioelectric potential difference across respiratory epithelia in cystic fibrosisN Engl J Med198130525148914957300874
   PubMed Web of Science ®Google Scholar
• Bangel-RulandNTomczakKWeberWMTargeting ENaC as a molecular suspect in cystic fibrosisCurr Drug Targets201516995195725544019
   PubMed Web of Science ®Google Scholar
• MatsuiHGrubbBRTarranREvidence for periciliary liquid layer depletion, not abnormal ion composition, in the pathogenesis of cystic fibrosis airways diseaseCell1998957100510159875854
   PubMed Web of Science ®Google Scholar
• CollawnJFLazrakABebokZMatalonSThe CFTR and ENaC debate: how important is ENaC in CF lung disease?Am J Physiol Lung Cell Mol Physiol201230211L1141L114622492740
   PubMed Web of Science ®Google Scholar
• HobbsCADa TanCTarranRDoes epithelial sodium channel hyperactivity contribute to cystic fibrosis lung disease?J Physiol2013591pt 184377438723878362
   PubMed Web of Science ®Google Scholar
• BerdievBKCormet-BoyakaEToussonAMolecular proximity of cystic fibrosis transmembrane conductance regulator and epithelial sodium channel assessed by fluorescence resonance energy transferJ Biol Chem200728250364813648817913705
   PubMed Web of Science ®Google Scholar
• JiHLChalfantMLJovovBThe cytosolic termini of the β- and γ- ENaC subunits are involved in the functional interactions between CFTR and ENaCJ Biol Chem200027536279472795610821834
   PubMed Web of Science ®Google Scholar
• KunzelmannKKiserGLSchreiberRRiordanJRInhibition of epithelial Na+ currents by intracellular domains of the cystic fibrosis transmembrane conductance regulatorFEBS Lett199740033413449009227
   PubMed Web of Science ®Google Scholar
• KonstasAAKochJPKorbmacherCcAMP-dependent activation of CFTR inhibits the epithelial sodium channel (ENaC) without affecting its surface expressionPflügers Arch2003445451352112548398
   PubMed Web of Science ®Google Scholar
• ChinetTCFulltonJMYankaskasJRBoucherRCStuttsMJMechanism of sodium hyperabsorption in cultured cystic fibrosis nasal epithelium: a patch-clamp studyAm J Physiol Cell Physiol19942664C1061C1068
   Web of Science ®Google Scholar
• GentzschMDangHDangYThe cystic fibrosis transmembrane conductance regulator impedes proteolytic stimulation of the epithelial Na(+) channelJ Biol Chem201028542322273223220709758
   PubMed Web of Science ®Google Scholar
• LuCJiangCPribanicSRotinDCFTR stabilizes ENaC at the plasma membraneJ Cyst Fibros20076641942217434346
   PubMed Web of Science ®Google Scholar
• HorisbergerJ-DENaC–CFTR interactions: the role of electrical coupling of ion fluxes explored in an epithelial cell modelPflügers Arch2003445452252812548399
   PubMed Web of Science ®Google Scholar
• KunzelmannKENaC is inhibited by an increase in the intracellular Cl− concentration mediated through activation of Cl− channelsPflügers Arch2003445450451212548397
   PubMed Web of Science ®Google Scholar
• KunzelmannKTianYMartinsJRAirway epithelial cells – functional links between CFTR and anoctamin dependent Cl− secretionInt J Biochem Cell Biol201244111897190022710346
   PubMed Web of Science ®Google Scholar
• El KhouriETouréAFunctional interaction of the cystic fibrosis transmembrane conductance regulator with members of the SLC26 family of anion transporters (SLC26A8 and SLC26A9): physiological and pathophysiological relevanceInt J Biochem Cell Biol201452586724530837
   PubMed Web of Science ®Google Scholar
• LoriolCDulongSAvellaMCharacterization of SLC26A9, facilitation of Cl- transport by bicarbonateCell Physiol Biochem2008221–4015030
   Google Scholar
• BertrandCAZhangRPilewskiJMFrizzellRASLC26A9 is a constitutively active, CFTR-regulated anion conductance in human bronchial epitheliaJ Gen Physiol2009133442143819289574
   PubMed Web of Science ®Google Scholar
• OusingsawatJSchreiberRKunzelmannKDifferential contribution of SLC26A9 to Cl− conductance in polarized and non-polarized epithelial cellsJ Gen Physiol2012227623232329
   Google Scholar
• HaardtMBenharougaMLechardeurDKartnerNLukacsGLC-terminal truncations destabilize the cystic fibrosis transmembrane conductance regulator without impairing its biogenesis: a novel class of mutationJ Biol Chem199927431218732187710419506
   PubMed Web of Science ®Google Scholar
• WelshMJSmithAEMolecular mechanisms of CFTR chloride channel dysfunction in cystic fibrosisCell1993737125112547686820
   PubMed Web of Science ®Google Scholar
• QuintALererISagiMAbeliovichDMutation spectrum in Jewish cystic fibrosis patients in Israel: implication to carrier screeningAm J Med Genet A2005136A324624815948195
   PubMed Web of Science ®Google Scholar
• ChengSHGregoryRJMarshallJDefective intracellular transport and processing of CFTR is the molecular basis of most cystic fibrosisCell19906348278341699669
   PubMed Web of Science ®Google Scholar
• DenningGMAndersonMPAmaraJFMarshallJSmithAEWelshMJProcessing of mutant cystic fibrosis transmembrane conductance regulator is temperature-sensitiveNature199235863897617641380673
   PubMed Web of Science ®Google Scholar
• BobadillaJLMacekMFineJPFarrellPMCystic fibrosis: a worldwide analysis of CFTR mutations – correlation with incidence data and application to screeningHum Mutat200219657560612007216
   PubMed Web of Science ®Google Scholar
• DalemansWBarbryPChampignyGAltered chloride ion channel kinetics associated with the ΔF508 cystic fibrosis mutationNature199135463545265281722027
   PubMed Web of Science ®Google Scholar
• VargaKGoldsteinRFJurkuvenaiteAEnhanced cell surface stability of rescued ΔF508 cystic fibrosis transmembrane conductance regulator by pharmacological chaperonesBiochem J2008410355556418052931
   PubMed Web of Science ®Google Scholar
• DeyIShahKBradburyNANatural compounds as therapeutic agents in the treatment cystic fibrosisJ Genet Syndr Gene Ther20167128427081574
   PubMedGoogle Scholar
• DrummMWilkinsonDSmitLChloride conductance expressed by delta F508 and other mutant CFTRs in Xenopus oocytesScience19912545039179717991722350
   PubMed Web of Science ®Google Scholar
• BecqFJensenTJChangXBPhosphatase inhibitors activate normal and defective CFTR chloride channelsProc Natl Acad Sci U S A19949119916091647522329
   PubMed Web of Science ®Google Scholar
• BecqFFanjulMMertenMFigarellaCHollandeEGolaMPossible regulation of CFTR-chloride channels by membrane-bound phosphatases in pancreatic duct cellsFEBS Lett199332733373427688697
   PubMed Web of Science ®Google Scholar
• ChappeVMetteyYVierfondJMStructural basis for specificity and potency of xanthine derivatives as activators of the CFTR chloride channelBr J Pharmacol199812346836939517388
   PubMed Web of Science ®Google Scholar
• CohenBELeeGJacobsonKA8-Cyclopentyl-1,3-dipropylxanthine and other xanthines differentially bind to the wild-type and ΔF508 mutant first nucleotide binding fold (NBF-1) domains of the cystic fibrosis transmembrane conductance regulatorBiochemistry19973621645564619174362
   PubMed Web of Science ®Google Scholar
• IllekBFischerHFlavonoids stimulate Cl conductance of human airway epithelium in vitro and in vivoAm J Physiol Lung Cell Mol Physiol19982755L902L910
   Web of Science ®Google Scholar
• FrenchPJBijmanJBotAGBoomaarsWEScholteBJde JongeHRGenistein activates CFTR Cl- channels via a tyrosine kinase- and protein phosphatase-independent mechanismAm J Physiol Cell Physiol19972732C747C753
   Web of Science ®Google Scholar
• IllekBFischerHSantosGFWiddicombeJHMachenTEReenstraWWcAMP-independent activation of CFTR Cl channels by the tyrosine kinase inhibitor genisteinAm J Physiol Cell Physiol19952684C886C893
   Web of Science ®Google Scholar
• HwangTCWangFYangICReenstraWWGenistein potentiates wild-type and delta F508-CFTR channel activityAm J Physiol19972733 pt 1C988C9989316420
   PubMed Web of Science ®Google Scholar
• IllekBZhangLLewisNCMossRBDongJYFischerHDefective function of the cystic fibrosis-causing missense mutation G551D is recovered by genisteinAm J Physiol Cell Physiol19992774C833C839
   Web of Science ®Google Scholar
• MoranOGaliettaLJVZegarra-MoranOBinding site of activators of the cystic fibrosis transmembrane conductance regulator in the nucleotide binding domainsCell Mol Life Sci200562444646015719171
   PubMed Web of Science ®Google Scholar
• WangWBernardKLiGKirkKLCurcumin opens cystic fibrosis transmembrane conductance regulator channels by a novel mechanism that requires neither ATP binding nor dimerization of the nucleotide-binding domainsJ Biol Chem200728274533454417178710
   PubMed Web of Science ®Google Scholar
• EganMEGlockner-PagelJAmbroseCACalcium-pump inhibitors induce functional surface expression of delF508-CFTR protein in cystic fibrosis epithelial cellsNat Med20028548549211984593
   PubMed Web of Science ®Google Scholar
• NorezCAntignyFBecqFVandebrouckCMaintaining low Ca2+ level in the endoplasmic reticulum restores abnormal endogenous F508del-CFTR trafficking in airway epithelial cellsTraffic20067556257316643279
   PubMed Web of Science ®Google Scholar
• EganMEPearsonMWeinerSACurcumin, a major constituent of turmeric, corrects cystic fibrosis defectsScience2004304567060060215105504
   PubMed Web of Science ®Google Scholar
• SongYSonawaneNDSalinasDEvidence against the rescue of defective ΔF508-CFTR cellular processing by curcumin in cell culture and mouse modelsJ Biol Chem200427939406294063315280357
   PubMed Web of Science ®Google Scholar
• GrubbBRGabrielSEMengosASERCA pump inhibitors do not correct biosynthetic arrest of ΔF508 CFTR in cystic fibrosisAm J Respir Cell Mol Biol200634335536316284361
   PubMed Web of Science ®Google Scholar
• YangSYuBSuiYCFTR chloride channel is a molecular target of the natural cancer preventive agent resveratrolPharmazie201368977277624147347
   PubMed Web of Science ®Google Scholar
• IllekBLizarzaburuMELeeVNantzMHKurthMJFischerHStructural determinants for activation and block of CFTR-mediated chloride currents by apigeninAm J Physiol Cell Physiol20002796C1838C184611078699
   PubMed Web of Science ®Google Scholar
• AlexanderNSHatchNZhangSResveratrol has salutary effects on mucociliary transport and inflammation in sinonasal epitheliumLaryngoscope201112161313131921480283
   PubMed Web of Science ®Google Scholar
• DhoogheBBouckaertCCapronAWallemacqPLealTNoelSResveratrol increases F508del-CFTR dependent salivary secretion in cystic fibrosis miceBiol Open20154792993626092868
   PubMed Web of Science ®Google Scholar
• WoodworthBAResveratrol ameliorates abnormalities of fluid and electrolyte secretion in a hypoxia-induced model of acquired CFTR deficiencyLaryngoscope2015125suppl 7S1S1325946147
   PubMed Web of Science ®Google Scholar
• HamdaouiNBaudoin-LegrosMKellyMResveratrol rescues cAMP-dependent anionic transport in the cystic fibrosis pancreatic cell line CFPAC1Br J Pharmacol2011163487688621366549
   PubMed Web of Science ®Google Scholar
• JaiYShahKBridgesRJBradburyNAEvidence against resveratrol as a viable therapy for the rescue of defective ΔF508 CFTRBiochim Biophys Acta20151850112377238426342647
   PubMed Web of Science ®Google Scholar
• Hay MeleBCitroVAndreottiGCubellisMVDrug repositioning can accelerate discovery of pharmacological chaperonesOrphanet J Rare Dis2015105525947946
   PubMed Web of Science ®Google Scholar
• SawkarARChengWCBeutlerEWongCHBalchWEKellyJWChemical chaperones increase the cellular activity of N370S β-glucosidase: a therapeutic strategy for Gaucher diseaseProc Natl Acad Sci U S A20029924154281543312434014
   PubMed Web of Science ®Google Scholar
• NoëlSWilkeMBotAGMDe JongeHRBecqFParallel improvement of sodium and chloride transport defects by miglustat (n-butyldeoxynojyrimicin) in cystic fibrosis epithelial cellsJ Pharmacol Exp Ther200832531016102318309088
   PubMed Web of Science ®Google Scholar
• NorezCNoelSWilkeMRescue of functional delF508-CFTR channels in cystic fibrosis epithelial cells by the α-glucosidase inhibitor miglustatFEBS Lett200658082081208616546175
   PubMed Web of Science ®Google Scholar
• LubambaBLebacqJLebecquePAirway delivery of low-dose miglustat normalizes nasal potential difference in F508del cystic fibrosis miceAm J Respir Crit Care Med2009179111022102819299496
   PubMed Web of Science ®Google Scholar
• LeonardALebecquePDingemanseJLealTA randomized placebo-controlled trial of miglustat in cystic fibrosis based on nasal potential differenceJ Cyst Fibros201211323123622281182
   PubMed Web of Science ®Google Scholar
• PeakTCYafiFASangkumPHellstromWJGEmerging drugs for the treatment of erectile dysfunctionExpert Opin Emerg Drugs201520226327525740087
   PubMed Web of Science ®Google Scholar
• HamblyNGrantonJRiociguat for the treatment of pulmonary hypertensionExpert Rev Respir Med20159667969526599488
   PubMed Web of Science ®Google Scholar
• LeierGBangel-RulandNSobczakKKnieperYWeberWMSildenafil acts as potentiator and corrector of CFTR but might be not suitable for the treatment of CF lung diseaseCell Physiol Biochem2012295–677579022613978
   PubMed Web of Science ®Google Scholar
• DormerRLHarrisCMClarkZSildenafil (Viagra) corrects ΔF508-CFTR location in nasal epithelial cells from patients with cystic fibrosisThorax2005601555915618584
   PubMed Web of Science ®Google Scholar
• DhoogheBNoëlSBouzinCBehets-WydemansGLealTCorrection of chloride transport and mislocalization of CFTR protein by vardenafil in the gastrointestinal tract of cystic fibrosis micePLoS One2013810e7731424204804
   PubMed Web of Science ®Google Scholar
• LubambaBLecourtHLebacqJPreclinical evidence that sildenafil and vardenafil activate chloride transport in cystic fibrosisAm J Respir Crit Care Med2008177550651518006891
   PubMed Web of Science ®Google Scholar
• Taylor-CousarJLWileyCFeltonLAPharmacokinetics and tolerability of oral sildenafil in adults with cystic fibrosis lung diseaseJ Cyst Fibros201514222823625466700
   PubMed Web of Science ®Google Scholar
• GhofraniHAGalièNGrimmingerFRiociguat for the treatment of pulmonary arterial hypertensionN Engl J Med2013369433034023883378
   PubMed Web of Science ®Google Scholar
• MittendorfJWeigandSAlonso-AlijaCDiscovery of riociguat (BAY 63-2521): a potent, oral stimulator of soluble guanylate cyclase for the treatment of pulmonary hypertensionChemMedChem20094585386519263460
   PubMed Web of Science ®Google Scholar
• KonstanMWSchluchterMDXueWDavisPBClinical use of ibuprofen is associated with slower FEV(1) decline in children with cystic fibrosisAm J Respir Crit Care Med2007176111084108917872492
   PubMed Web of Science ®Google Scholar
• CarlileGWRobertRGoeppJIbuprofen rescues mutant cystic fibrosis transmembrane conductance regulator traffickingJ Cyst Fibros2015141162524974227
   PubMed Web of Science ®Google Scholar
• GahlWAEarly oral cysteamine therapy for nephropathic cystinosisEur J Pediatr20031621S38S4114610675
   PubMed Web of Science ®Google Scholar
• LucianiAVillellaVREspositoSDefective CFTR induces aggresome formation and lung inflammation in cystic fibrosis through ROS-mediated autophagy inhibitionNat Cell Biol201012986387520711182
   PubMed Web of Science ®Google Scholar
• AbdulrahmanBAKhweekAAAkhterAAutophagy stimulation by rapamycin suppresses lung inflammation and infection by Burkholderia cenocepacia in a model of cystic fibrosisAutophagy20117111359137021997369
   PubMed Web of Science ®Google Scholar
• LucianiAVillellaVREspositoSTargeting autophagy as a novel strategy for facilitating the therapeutic action of potentiators on ΔF508 cystic fibrosis transmembrane conductance regulatorAutophagy20128111657167222874563
   PubMed Web of Science ®Google Scholar
• StefanoDDVillellaVREspositoSRestoration of CFTR function in patients with cystic fibrosis carrying the F508del-CFTR mutationAutophagy201410112053207425350163
   PubMed Web of Science ®Google Scholar
• ToscoADe GregorioFEspositoSA novel treatment of cystic fibrosis acting on-target: cysteamine plus epigallocatechin gallate for the autophagy-dependent rescue of class II-mutated CFTRCell Death Differ Epub2016722
   Web of Science ®Google Scholar
• SirtoriCRAescin: pharmacology, pharmacokinetics and therapeutic profilePharmacol Res200144318319311529685
   PubMed Web of Science ®Google Scholar
• MutyamVDuMXueXDiscovery of clinically approved agents that promote suppression of CFTR nonsense mutationsAm J Respir Crit Care Med Epub2016422
   Web of Science ®Google Scholar
• MaTVetrivelLYangHHigh-affinity activators of cystic fibrosis transmembrane conductance regulator (CFTR) chloride conductance identified by high-throughput screeningJ Biol Chem200227740372353724112161441
   PubMed Web of Science ®Google Scholar
• PedemonteNLukacsGLDuKSmall-molecule correctors of defective ΔF508-CFTR cellular processing identified by high-throughput screeningJ Clin Invest200511592564257116127463
   PubMed Web of Science ®Google Scholar
• Van GoorFStraleyKSCaoDRescue of ΔF508-CFTR trafficking and gating in human cystic fibrosis airway primary cultures by small moleculesAm J Physiol Lung Cell Mol Physiol20062906L1117L113016443646
   PubMed Web of Science ®Google Scholar
• Sermet-GaudelusIRenouilMFajacAIn vitro prediction of stop-codon suppression by intravenous gentamicin in patients with cystic fibrosis: a pilot studyBMC Med200755517394637
   PubMed Web of Science ®Google Scholar
• HowardMFrizzellRABedwellDMAminoglycoside antibiotics restore CFTR function by overcoming premature stop mutationsNat Med1996244674698597960
   PubMed Web of Science ®Google Scholar
• BedwellDMKaenjakABenosDJSuppression of a CFTR premature stop mutation in a bronchial epithelial cell lineNat Med1997311128012849359706
   PubMed Web of Science ®Google Scholar
• WilschanskiMYahavYYaacovYGentamicin-induced correction of CFTR function in patients with cystic fibrosis and CFTR stop mutationsN Engl J Med2003349151433144114534336
   PubMed Web of Science ®Google Scholar
• WilschanskiMFaminiCBlauHA pilot study of the effect of gentamicin on nasal potential difference measurements in cystic fibrosis patients carrying stop mutationsAm J Respir Crit Care Med2000161386086510712334
   PubMed Web of Science ®Google Scholar
• ClancyJPBebökZRuizFEvidence that systemic gentamicin suppresses premature stop mutations in patients with cystic fibrosisAm J Respir Crit Care Med200116371683169211401894
   PubMed Web of Science ®Google Scholar
• ClancyJPRoweSMBebokZNo detectable improvements in cystic fibrosis transmembrane conductance regulator by nasal aminoglycosides in patients with cystic fibrosis with stop mutationsAm J Respir Cell Mol Biol2007371576617347447
   PubMed Web of Science ®Google Scholar
• NudelmanIRebibo-SabbahACherniavskyMDevelopment of novel aminoglycoside (NB54) with reduced toxicity and enhanced suppression of disease-causing premature stop mutationsJ Med Chem20095292836284519309154
   PubMed Web of Science ®Google Scholar
• SabbavarapuNMShavitMDeganiYSmolkinBBelakhovVBaasovTDesign of novel aminoglycoside derivatives with enhanced suppression of diseases-causing nonsense mutationsACS Med Chem Lett20167441842327096052
   PubMed Web of Science ®Google Scholar
• XueXMutyamVTangLSynthetic aminoglycosides efficiently suppress cystic fibrosis transmembrane conductance regulator nonsense mutations and are enhanced by ivacaftorAm J Respir Cell Mol Biol201450480581624251786
   PubMed Web of Science ®Google Scholar
• RoweSMSloanePTangLPSuppression of CFTR premature termination codons and rescue of CFTR protein and function by the synthetic aminoglycoside NB54J Mol Med (Berl)201189111149116121779978
   PubMed Web of Science ®Google Scholar
• DuMJonesJRLanierJAminoglycoside suppression of a premature stop mutation in a Cftr−/− mouse carrying a human CFTR-G542X transgeneJ Mol Med (Berl)200280959560412226741
   PubMed Web of Science ®Google Scholar
• HamedSDrug evaluation: PTC-124: a potential treatment of cystic fibrosis and Duchenne muscular dystrophyIDrugs200691178378917096300
   PubMed Web of Science ®Google Scholar
• KeremEHirawatSArmoniSEffectiveness of PTC124 treatment of cystic fibrosis caused by nonsense mutations: a prospective phase II trialLancet2008372964071972718722008
   PubMed Web of Science ®Google Scholar
• Sermet-GaudelusIDe BoeckKCasimirGJAtaluren (PTC124) induces cystic fibrosis transmembrane conductance regulator protein expression and activity in children with nonsense mutation cystic fibrosisAm J Respir Crit Care Med2010182101262127220622033
   PubMed Web of Science ®Google Scholar
• KeremEKonstanMWDe BoeckKCystic Fibrosis Ataluren Study GroupAtaluren for the treatment of nonsense-mutation cystic fibrosis: a randomised, double-blind, placebo-controlled phase 3 trialLancet Respir Med20142753954724836205
   PubMed Web of Science ®Google Scholar
• BrownCRHong-BrownLQBiwersiJVerkmanASWelchWJChemical chaperones correct the mutant phenotype of the ΔF508 cystic fibrosis transmembrane conductance regulator proteinCell Stress Chaperones1996121171259222597
   PubMed Web of Science ®Google Scholar
• SatoSWardCLKrouseMEWineJJKopitoRRGlycerol reverses the misfolding phenotype of the most common cystic fibrosis mutationJ Biol Chem199627126356388557666
   PubMed Web of Science ®Google Scholar
• MoyerBDLoffing-CueniDLoffingJReynoldsDStantonBAButyrate increases apical membrane CFTR but reduces chloride secretion in MDCK cellsAm J Physiol19992772F271F27610444582
   PubMedGoogle Scholar
• RubensteinRCEganMEZeitlinPLIn vitro pharmacologic restoration of CFTR-mediated chloride transport with sodium 4-phenylbutyrate in cystic fibrosis epithelial cells containing delta F508-CFTRJ Clin Invest199710010245724659366560
   PubMed Web of Science ®Google Scholar
• RubensteinRCZeitlinPLSodium 4-phenylbutyrate downregulates Hsc70: implications for intracellular trafficking of ΔF508-CFTRAm J Physiol Cell Physiol20002782C259C26710666020
   PubMed Web of Science ®Google Scholar
• RubensteinRZeitlinPA pilot clinical trial of oral sodium 4-phenylbutyrate (Buphenyl) in Δ F508-homozygous cystic fibrosis patientsAm J Respir Crit Care Med199815724844909476862
   PubMed Web of Science ®Google Scholar
• LooTBartlettMClarkeDCorrectors promote folding of the CFTR in the endoplasmic reticulumBiochem J20084131293618361776
   PubMed Web of Science ®Google Scholar
• LooTBartlettMWangYClarkeDThe chemical chaperone CFcor-325 repairs folding defects in the transmembrane domains of CFTR-processing mutantsBiochem J2006395pt 353754216417523
   PubMed Web of Science ®Google Scholar
• HuttDMHermanDRodriguesAPCReduced histone deacetylase 7 activity restores function to misfolded CFTR in cystic fibrosisNat Chem Biol201061253319966789
   PubMed Web of Science ®Google Scholar
• SampsonHRobertRLiaoJIdentification of a NBD1-binding pharmacological chaperone that corrects the trafficking defect of F508del-CFTRChem Biol201118223124221338920
   PubMed Web of Science ®Google Scholar
• RenHYGroveDEDe La RosaOVX-809 corrects folding defects in cystic fibrosis transmembrane conductance regulator protein through action on membrane-spanning domain 1Mol Biol Cell201324193016302423924900
   PubMed Web of Science ®Google Scholar
• Van GoorFHadidaSGrootenhuisPDJCorrection of the F508del-CFTR protein processing defect in vitro by the investigational drug VX-809Proc Natl Acad Sci U S A201110846188431884821976485
   PubMed Web of Science ®Google Scholar
• ClancyJPRoweSMAccursoFJResults of a phase IIa study of VX-809, an investigational CFTR corrector compound, in subjects with cystic fibrosis homozygous for the F508del-CFTR mutationThorax2012671121821825083
   PubMed Web of Science ®Google Scholar
• BoyleMPBellSCKonstanMWVX09-809-102 Study GroupA CFTR corrector (lumacaftor) and a CFTR potentiator (ivacaftor) for treatment of patients with cystic fibrosis who have a phe508del CFTR mutation: a phase 2 randomised controlled trialLancet Respir Med20142752753824973281
   PubMed Web of Science ®Google Scholar
• WainwrightCEElbornJSRamseyBWLumacaftor–ivacaftor in patients with cystic fibrosis homozygous for Phe508del CFTRN Engl J Med2015373322023125981758
   PubMed Web of Science ®Google Scholar
• JonesAMBarryPJLumacaftor/ivacaftor for patients homozygous for Phe508del-CFTR: should we curb our enthusiasm?Thorax201570761561626071414
   PubMed Web of Science ®Google Scholar
• OrensteinDMO’SullivanBPQuintonPMCystic fibrosis: breakthrough drugs at break-the-bank pricesGlob Adv Health Med20154685726659555
   PubMedGoogle Scholar
• CholonDMQuinneyNLFulcherMLPotentiator ivacaftor abrogates pharmacological correction of ΔF508 CFTR in cystic fibrosisSci Transl Med20146246246ra296
   Web of Science ®Google Scholar
• VeitGAvramescuRGPerdomoDSome gating potentiators, including VX-770, diminish ΔF508-CFTR functional expressionSci Transl Med20146246246ra297
   Web of Science ®Google Scholar
• PilewskiJMCookeJLekstrom-HimesJDonaldsonSWS01.4 VX-661 in combination with ivacaftor in patients with cystic fibrosis and the F508del-CFTR mutationJ Cyst Fibros201514S1
   PubMed Web of Science ®Google Scholar
• BeumerWSwildensJHenigNWS01.2 QR-010, an RNA therapy, restores CFTR function using in vitro and in vivo models of delF508 CFTRJ Cyst Fibros201514S1
   PubMed Web of Science ®Google Scholar
• HenigNBeumerWAnthonijszHQR-010, an RNA Therapy, Restores CFTR Function in the Saliva Secretion AssayA37. It Won’t be Long: Advances in Adult Cystic FibrosisNew York, NYAmerican Thoracic Society2015A1449A1449
   Google Scholar
• Van GoorFHadidaSGrootenhuisPDJRescue of CF airway epithelial cell function in vitro by a CFTR potentiator, VX-770Proc Natl Acad Sci U S A200910644188251883019846789
   PubMed Web of Science ®Google Scholar
• AccursoFJRoweSMClancyJPEffect of VX-770 in persons with cystic fibrosis and the G551D-CFTR mutationN Engl J Med2010363211991200321083385
   PubMed Web of Science ®Google Scholar
• DaviesJSheridanHBellNAssessment of clinical response to ivacaftor with lung clearance index in cystic fibrosis patients with a G551D-CFTR mutation and preserved spirometry: a randomised controlled trialLancet Respir Med20131863063824461666
   PubMed Web of Science ®Google Scholar
• RamseyBWDaviesJMcElvaneyNGVX08-770-102 Study GroupA CFTR potentiator in patients with cystic fibrosis and the G551D mutationN Engl J Med2011365181663167222047557
   PubMed Web of Science ®Google Scholar
• De BoeckKMunckAWalkerSEfficacy and safety of ivacaftor in patients with cystic fibrosis and a non-G551D gating mutationJ Cyst Fibros201413667468025266159
   PubMed Web of Science ®Google Scholar
• DaviesJCCunninghamSHarrisWTSafety, pharmacokinetics, and pharmacodynamics of ivacaftor in patients aged 2–5 years with cystic fibrosis and a CFTR gating mutation (KIWI): an open-label, single-arm studyLancet Respir Med20164210711526803277
   PubMed Web of Science ®Google Scholar
• FlumePALiouTGBorowitzDSVX 08-770-104 Study GroupIvacaftor in subjects with cystic fibrosis who are homozygous for the F508del-CFTR mutationChest2012142371872422383668
   PubMed Web of Science ®Google Scholar
• UttamsinehVPiljaLGrotbeckBWS13.6 CTP-656 tablet confirmed superiority of pharmacokinetic profile relative to Kalydeco® in phase I clinical studiesJ Cyst Fibros201615S1S22
   Google Scholar
• ShamsahKJoseALaurieDQBW251 is a safe and efficacious CFTR potentiator for patients with cystic fibrosisAm J Respir Crit Care Med2016193A7789
   Google Scholar
• VanhoutteFPGouyMHaazenWSafety, tolerability and pharmacokinetics of a novel CFTR potentiator GPLG1837 in healthy volunteersPediatr Pulmonol201550S41S289
   Google Scholar
• MarozkinaNVYemenSBorowitzMHsp 70/Hsp 90 organizing protein as a nitrosylation target in cystic fibrosis therapyProc Natl Acad Sci U S A201010725113931139820534503
   PubMed Web of Science ®Google Scholar
• ZamanKSawczakVZaidiAAugmentation of CFTR maturation by S-nitrosoglutathione reductaseAm J Physiol Lung Cell Mol Physiol20163103L263L27026637637
   PubMed Web of Science ®Google Scholar
• ZamanKCarraroSDohertyJS-nitrosylating agents: a novel class of compounds that increase cystic fibrosis transmembrane conductance regulator expression and maturation in epithelial cellsMol Pharmacol20067041435144216857740
   PubMed Web of Science ®Google Scholar
• Taylor-CousarJZemanickESolomonGThe pharmacokinetics of N91115, an inhibitor of S-nitrosoglutathione reductase in cystic fibrosis patientsPediatr Pulmonol201550S41S285S286
   Google Scholar
• MillerJDrewLGreenOAmplifiers are a new class of CFTR modulators that increase the abundance of CFTR protein and combined with potentiators and correctors enhance chloride transport activityPediatr Pulmonol201550S41S265
   Google Scholar
• DhoogheBHaafJBNoelSLealTStrategies in early clinical development for the treatment of basic defects of cystic fibrosisExpert Opin Investig Drugs2016254423436
   PubMed Web of Science ®Google Scholar